Key issues that need to be urgently addressed include: how to use the metabolic differences between T cell subsets (e.g., Tregs rely on FAO and CD8+ T cells rely on glycolysis) to design selective regulation strategies; the safety and efficacy of selenium supplements or CD36 inhibitors in tumor immunotherapy still need to be verified in large-scale clinical trials. Here, CD36 is linked to neoplasm.